Discrepant NOXA (PMAIP1) transcript and NOXA protein levels: a potential Achilles' heel in mantle cell lymphoma

[1]  Michael L. Wang,et al.  Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. , 2013, The New England journal of medicine.

[2]  J. Friedberg,et al.  The Bruton tyrosine kinase (BTK) inhibitor PCI‐32765 synergistically increases proteasome inhibitor activity in diffuse large‐B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib , 2013, British journal of haematology.

[3]  Michael J. Schell,et al.  Ubiquitin C-terminal hydrolase-L1 potentiates cancer chemosensitivity by stabilizing NOXA. , 2013, Cell reports.

[4]  L. Staudt,et al.  Targeting pathological B cell receptor signalling in lymphoid malignancies , 2013, Nature Reviews Drug Discovery.

[5]  M. Oren,et al.  Cisplatin hypersensitivity of testicular germ cell tumors is determined by high constitutive Noxa levels mediated by Oct-4. , 2013, Cancer research.

[6]  S. Kulp,et al.  Targeting the Oncogenic E3 Ligase Skp2 in Prostate and Breast Cancer Cells with a Novel Energy Restriction-Mimetic Agent , 2012, PloS one.

[7]  E. Campo,et al.  Molecular pathogenesis of mantle cell lymphoma. , 2012, The Journal of clinical investigation.

[8]  H. Kang,et al.  The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells. , 2012, Leukemia research.

[9]  S. Grant,et al.  Proteasome inhibitors in mantle cell lymphoma. , 2012, Best practice & research. Clinical haematology.

[10]  R. Bale,et al.  First experience with proteasome inhibitor treatment of radioiodine nonavid thyroid cancer using bortezomib. , 2012, Clinical nuclear medicine.

[11]  A. Belch,et al.  Blockade of Fatty Acid Synthase Triggers Significant Apoptosis in Mantle Cell Lymphoma , 2012, PloS one.

[12]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[13]  R. V. van Lier,et al.  BH3-only protein Noxa regulates apoptosis in activated B cells and controls high-affinity antibody formation. , 2012, Blood.

[14]  U. Hofmann,et al.  Oncogenic Stress Induced by Acute Hyper-Activation of Bcr-Abl Leads to Cell Death upon Induction of Excessive Aerobic Glycolysis , 2011, PloS one.

[15]  M. Oren,et al.  p53 Hypersensitivity Is the Predominant Mechanism of the Unique Responsiveness of Testicular Germ Cell Tumor (TGCT) Cells to Cisplatin , 2011, PloS one.

[16]  Di Chen,et al.  Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. , 2011, Current cancer drug targets.

[17]  Xiangao Huang,et al.  Noxa mediates p18INK4c cell-cycle control of homeostasis in B cells and plasma cell precursors. , 2011, Blood.

[18]  A. Wiestner,et al.  Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. , 2011, Blood.

[19]  Mark Manfredi,et al.  MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma. , 2010, Blood.

[20]  M. Butterworth,et al.  Role of NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells , 2010, Haematologica.

[21]  Francis J Giles,et al.  Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. , 2010, Blood.

[22]  M. Loda,et al.  Fatty acid synthase as a potential therapeutic target in cancer. , 2010, Future oncology.

[23]  Yi Sun,et al.  Validation of SAG/RBX2/ROC2 E3 Ubiquitin Ligase as an Anticancer and Radiosensitizing Target , 2010, Clinical Cancer Research.

[24]  Amanda Doucette,et al.  An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer , 2009, Nature.

[25]  R. Kofler,et al.  Noxa: at the tip of the balance between life and death , 2008, Oncogene.

[26]  C. Doglioni,et al.  Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma. , 2008, Blood.

[27]  M. Ohira,et al.  Stress via p53 pathway causes apoptosis by mitochondrial Noxa upregulation in doxorubicin-treated neuroblastoma cells , 2008, Oncogene.

[28]  W. Xie,et al.  Noxa/Mcl-1 balance regulates susceptibility of cells to camptothecin-induced apoptosis. , 2007, Neoplasia.

[29]  E. Campo,et al.  Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics , 2007, Nature Reviews Cancer.

[30]  S. Cory,et al.  The Bcl-2 apoptotic switch in cancer development and therapy , 2007, Oncogene.

[31]  G. Basso,et al.  Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma , 2007, Leukemia.

[32]  D. McMillin,et al.  Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro. , 2006, The Journal of clinical endocrinology and metabolism.

[33]  Ling Tian,et al.  Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. , 2006, Cancer research.

[34]  A. Rosenwald,et al.  Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  G. Melino,et al.  E1A Activates Transcription of p73 and Noxa to Induce Apoptosis* , 2005, Journal of Biological Chemistry.

[36]  H. Tagawa,et al.  Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM , 2005, Oncogene.

[37]  Jeffrey W. Smith,et al.  A Fatty Acid Synthase Blockade Induces Tumor Cell-cycle Arrest by Down-regulating Skp2* , 2004, Journal of Biological Chemistry.

[38]  D. Ginsberg,et al.  Up-regulation of Bcl-2 Homology 3 (BH3)-only Proteins by E2F1 Mediates Apoptosis* , 2004, Journal of Biological Chemistry.

[39]  S. de Vos,et al.  Altered Apoptosis Pathways in Mantle Cell Lymphoma , 2004, Leukemia & lymphoma.

[40]  Nerea Martínez,et al.  The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. , 2003, Cancer research.

[41]  C. Miething,et al.  Adhesion to fibronectin selectively protects Bcr-Abl+ cells from DNA damage-induced apoptosis. , 2001, Blood.

[42]  A. Strasser,et al.  The BCL-2 protein family: opposing activities that mediate cell death , 2008, Nature Reviews Molecular Cell Biology.

[43]  E. Campo,et al.  The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. , 2006, Blood.